Technology ID

Brachyury-directed Vaccine for the Prevention or Treatment of Cancers

Lead Inventor
Schlom, Jeffrey (NCI)
Palena, Claudia (NCI)
Therapeutic Areas
Development Stages
Clinical Phase I
Lead IC

Tumor invasion and metastasis are the primary drivers of cancer-related mortality. Therapies that have an ability to specifically target invasive and/or metastatic cells are anticipated to have a significant impact in the clinical management of advanced cancers.

Researchers at the NCI have developed a vaccine technology that stimulates the immune system to selectively destroy metastasizing cells. Brachyury, a master transcription factor that governs the epithelial-mesenchymal transition, was shown to be significantly overexpressed in primary and metastasizing tumors relative to normal human tissues. Stimulation of T cells with the Brachyury peptide promoted a robust immune response and the targeted lysis of invasive tumor cells. Brachyury overexpression has been demonstrated in a range of human tumors (breast, lung, colon and prostate, among others) suggesting that a therapeutic vaccine derived from this technology would be broadly applicable for the treatment of cancer.

Competitive Advantages:

  • Treatment targets invasive and metastatic tumor cells which are the primary cause of cancer-related mortality.
  • Vaccine can eliminate cancer stem cells which are resistant to conventional therapies
  • Compatible with the clinically-proven TRICOM cancer vaccine platform
  • Available (Optimized) for use with non-pox, non-yeast vectors including: adenovirus, lentivirus, etc., and for use with protein- or peptide-based vaccines

Commercial Applications:

  • Preventative cancer vaccine for patients with precancerous lesions of the breast, colon or prostate.
  • Therapeutic cancer vaccine for the treatment of disseminated and late-stage tumors.
  • Vaccine component of a multi-modal cancer therapy
Licensing Contact:
Pollack, Michael